Lilly Endowment INC Position in Eli Lilly And Company (LLY) Has Lowered as Stock Value Rose

September 14, 2018 - By Rachel Eickhoff

Eli Lilly and Company (NYSE:LLY) LogoInvestors sentiment increased to 0.84 in 2018 Q2. Its up 0.06, from 0.78 in 2018Q1. It increased, as 51 investors sold LLY shares while 414 reduced holdings. 112 funds opened positions while 280 raised stakes. 808.82 million shares or 0.26% less from 810.94 million shares in 2018Q1 were reported. Wellington Grp Limited Liability Partnership holds 1.05% or 55.25M shares in its portfolio. Natl Insurance Tx owns 172,370 shares. Natl Bank Hapoalim Bm, a Israel-based fund reported 9,185 shares. 25,559 are owned by Palisade Asset Management Limited Com. 49,320 are owned by Colonial Tru Advisors. 4,955 are held by First State Bank. Rnc Mngmt Ltd invested 2.85% in Eli Lilly and Company (NYSE:LLY). Private Advisor Ltd Limited Liability Company holds 0.06% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 39,774 shares. 11.31M were reported by Northern Tru Corporation. Brown Advisory Incorporated reported 158,873 shares. Teachers Retirement Sys Of The State Of Kentucky reported 0.18% stake. South Dakota Inv Council holds 0.09% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 50,600 shares. Country Financial Bank has invested 1.19% in Eli Lilly and Company (NYSE:LLY). Cullinan Assoc Inc has invested 0.22% in Eli Lilly and Company (NYSE:LLY). Tci Wealth Advsrs Inc holds 0.54% or 14,216 shares.

Since March 16, 2018, it had 2 insider purchases, and 25 sales for $273.51 million activity. The insider Zakrowski Donald A sold $63,342. LILLY ENDOWMENT INC had sold 11,104 shares worth $957,953 on Wednesday, June 13. Simmons Jeffrey N had sold 9,027 shares worth $708,620. The insider Conterno Enrique A sold $2.13M. On Thursday, June 14 Skovronsky Daniel bought $862,200 worth of Eli Lilly and Company (NYSE:LLY) or 10,000 shares. Shares for $691,775 were sold by Shaw Christi.

Lilly Endowment Inc decreased its stake in Eli Lilly And Company (LLY) by 0.83% based on its latest 2018Q2 regulatory filing with the SEC. Lilly Endowment Inc sold 1.03M shares as the company’s stock rose 23.62% with the market. The institutional investor held 122.05 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $10.41 billion, down from 123.08M at the end of the previous reported quarter. Lilly Endowment Inc who had been investing in Eli Lilly And Company for a number of months, seems to be less bullish one the $107.87 billion market cap company. The stock decreased 0.68% or $0.73 during the last trading session, reaching $105.85. About 932,004 shares traded. Eli Lilly and Company (NYSE:LLY) has risen 28.96% since September 14, 2017 and is uptrending. It has outperformed by 13.34% the S&P500.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on October, 23. They expect $1.35 EPS, up 28.57 % or $0.30 from last year’s $1.05 per share. LLY’s profit will be $1.38B for 19.60 P/E if the $1.35 EPS becomes a reality. After $1.50 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts -10.00 % negative EPS growth.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Seekingalpha.com which released: “Eli Lilly and Co (LLY) Presents at Morgan Stanley Healthcare Conference Broker Conference (Transcript)” on September 13, 2018, also Forbes.com with their article: “Elanco Animal Health Announces IPO Price Range” published on September 12, 2018, Streetinsider.com published: “Lilly (LLY) to Showcase New Data at EADV Congress” on September 10, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: 247Wallst.com and their article: “Short Sellers Back Off Major Pharma Stocks” published on September 13, 2018 as well as Seekingalpha.com‘s news article titled: “Neuroscience In Big Pharma: Eli Lilly” with publication date: August 20, 2018.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 11 analysts covering Eli Lilly & Co (NYSE:LLY), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Eli Lilly & Co had 19 analyst reports since March 23, 2018 according to SRatingsIntel. The firm earned “Underperform” rating on Thursday, June 21 by Credit Suisse. On Wednesday, July 25 the stock rating was maintained by BMO Capital Markets with “Market Perform”. Jefferies maintained Eli Lilly and Company (NYSE:LLY) on Friday, April 13 with “Buy” rating. On Wednesday, April 25 the stock rating was maintained by BMO Capital Markets with “Market Perform”. On Tuesday, July 31 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The company was downgraded on Wednesday, July 25 by Berenberg. The company was maintained on Monday, June 11 by J.P. Morgan. On Friday, March 23 the stock rating was maintained by Jefferies with “Buy”. The firm has “Overweight” rating given on Wednesday, July 25 by Cantor Fitzgerald. The rating was upgraded by BMO Capital Markets on Friday, April 13 to “Market Perform”.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.